Symptoms of depression and diabetes-specific emotional distress are associated with a negative appraisal of insulin therapy in insulin-naïve patients with Type 2 diabetes mellitus. A study from the European Depression in Diabetes [EDID] research consortium


Published in:
Diabetic Medicine: Journal of Diabetes UK

Publication date:
2009

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Original Article: Psychological Issues and Education

Symptoms of depression and diabetes-specific emotional distress are associated with a negative appraisal of insulin therapy in insulin-naïve patients with Type 2 diabetes mellitus. A study from the European Depression in Diabetes [EDID] Research Consortium

C. Makine*, Ç. Karşıdağ†, P. Kadioğlu‡, H. Ilkova‡, K. Karşıdağ§, S. E. Skovlund¶, F. J. Snoek* and F. Pouwer**

*Department of Medical Psychology, EMGO Institute, VU University Medical Center, Amsterdam, The Netherlands, †Bakirkoy Mental and Neurological Disease Hospital, Istanbul, Turkey, ‡Istanbul University, Cerrahpasa Medical Faculty, Turkey, §Istanbul University, Istanbul Medical Faculty, Turkey, ¶Novo Nordisk, Bagsværd, Denmark, **Centre of Research on Psychology in Somatic diseases (CoRPS), Tilburg University, Tilburg, The Netherlands

Accepted 3 October 2008

Abstract

Aims A meta-analysis concluded that depression is associated with poor glycaemic control in Type 2 diabetes (DM2). In DM2 patients with deteriorating glycaemic control, the initiation of insulin therapy is often postponed. The aim of the present study was to determine whether symptoms of depression and diabetes-specific emotional distress are associated with a more negative appraisal of insulin therapy.

Methods We collected cross-sectional data in two outpatient university clinics in Istanbul, Turkey. The study sample consisted of 154 insulin-naïve patients with DM2. A self-report questionnaire was used to obtain demographic and clinical data. Main instruments were the Centre for Epidemiologic Studies Depression Scale, (CES-D), the Problem Areas In Diabetes scale (PAID) and the Insulin Treatment Appraisal Scale (ITAS).

Results Analysis of variance revealed that patients with a higher depression score rated insulin therapy significantly more negative than patients with lower depression scores. Moreover, 47% of patients with a high depression score had a negative appraisal of insulin therapy on 7 or more of the 20 ITAS-items, compared to 25 to 29% of those with low-moderate depression scores. Multiple regression analyses showed that a negative appraisal of insulin therapy was significantly associated with higher depression and diabetes-distress scores and low education, but not with sex, age or duration of diabetes.

Conclusions Our results suggest that in insulin-naïve Type 2 diabetes patients, higher levels of depression and diabetes-distress tend to be associated with more negative beliefs about insulin. Whether these negative attitudes translate into postponing initiation of insulin therapy needs to be tested in longitudinal research.


Keywords diabetes mellitus, depression, insulin

Abbreviations CES-D, Center for Epidemiologic Studies Depression Scale; ITAS, Insulin Treatment Appraisal Scale

Introduction

Depression can be regarded as a serious and common complication of diabetes, as a recent meta-analysis concluded that depression is 2–3 times more prevalent in people with diabetes than in the general population, affecting 10–15% of the diabetes patients [1]. Moreover, depression in diabetes is associated with...
with impaired glycemic control, and as a consequence depressed diabetes patients are at a higher risk for long-term complications of the disease [2,3].

Although results of the United Kingdom Prospective Diabetes Study (UKPDS) have shown convincingly that good glycemic control can prevent or delay the onset of diabetes complications in Type 2 diabetes patients, a reluctance to start insulin therapy has been observed in many patients with Type 2 diabetes [4–7].

Only a few studies have reported results regarding the prevalence of negative appraisals of insulin, or ‘psychological insulin resistance’. For example, in the UKPDS, 27% of the patients randomized to insulin therapy initially refused insulin, compared to 7% in the Glibenclamide group and 13% in the Chlorpropamide group [4]. A study by Polonsky et al. had comparable results, showing that about 28% of insulin-naive diabetes patients reported to be unwilling to begin insulin if prescribed [6]. Hence, these results suggest that considerably strong, negative appraisals regarding insulin therapy exist in about one third of the insulin-naive patients. However, the determinants of a negative appraisal of insulin therapy are still unclear. A negative appraisal of insulin therapy was found to be more common in women compared to men (31% versus 21%) and in ethnic minorities versus whites (35% versus 22%) [6].

Besides low mood, depressed patients often complain about reduced energy and low self-efficacy, resulting in difficulty finishing tasks and a decreased motivation in undertaking new projects [8]. We can therefore hypothesize that higher levels of depressive symptoms are associated with a more negative appraisal of insulin therapy, that could result in postponing initiation of insulin treatment. In this cross-sectional study we aimed to test whether depression and diabetes distress are associated with a more negative attitude towards insulin in a group patients with Type 2 diabetes treated with diet and/or oral agents.

Research design and methods

This study was conducted in two outpatient clinics in Istanbul, Turkey: the Istanbul Medical Faculty Hospital and the Cerrahpaşa Medical Faculty Hospital. The Cerrahpaşa Medical Faculty Hospital is a tertiary clinic serving approximately 10 000 patients with diabetes annually.

We aimed to include a sample of at least 150 insulin-naive patients with Type 2 diabetes. Therefore, we invited consecutive patients with Type 2 diabetes mellitus who were treated with a diet and/or oral agents. Exclusion criteria for this study were being illiterate or not being able to read due to vision problems. All subjects gave written informed consent and the Ethical Review Committee of the Istanbul University Medical Faculty and Cerrahpaşa Medical Faculty approved the study.

Measures

Demographic data and information regarding medical treatments for diabetes and depression were obtained from self-report and HbA1c values were collected using the medical charts of participants.

Appraisal of Insulin Therapy Scale

The Insulin Treatment Appraisal Scale (ITAS) has been developed to assess attitudes towards insulin treatment and contains 20 items (16 negative, 4 positive statements) that are scored on a 5 point Likert scale, ranging from strongly disagree to strongly agree. The topics covered in ITAS include for example that insulin signifies: feeling sicker, being more dependent, having a higher risk of hypoglycemia, painful injections, being restricted in daily life, being protected from complications or feeling more energetic. The ITAS appeared to have satisfactory psychometric qualities for diagnostic and research purposes in relation to perceptual barriers to insulin therapy [9]. To date, Cronbach’s alpha was 0.88 and item-total correlations were all larger than 0.25. The total ITAS score is calculated as the sum of the 20 items, where a higher score indicates a more negative perception of insulin therapy. In the present samples, Cronbach’s alpha was 0.82 and 0.87 for the in the Istanbul University Clinic and Cerrahpaşa University Clinic respectively.

Depression

Depression was assessed using the Turkish version of the Centre for Epidemiologic Studies Depression Scale (CES-D). This is a 20-item, self-report scale that asks respondents to indicate the frequency of occurrence of 20 depression symptoms during the last week. The instrument uses a four-point response set, ranging from ‘rarely or none of the time’ to ‘most or all of the time’. Higher scores indicate more depressive symptoms and a cut-off point of 16 or more is generally accepted as indicative of a clinically significant level of depression symptoms [10–12].

Diabetes-specific emotional distress

The Problem Areas in Diabetes (PAID) scale is a 20 item, self-report scale that asks individuals to rate how much of a problem, on a five-point scale (‘not a problem’ to ‘serious problem’) they find each of the 20 issues raised [13]. The items consist of 20 statements that Polonsky and colleagues identified as common negative emotions related to living with diabetes, for example ‘feeling alone with diabetes’, ‘worrying about the future and the possibility of serious complications’. The PAID scores are summed and transformed to a 0–100 scale, with higher scores indicating higher emotional problems. The ITAS and the PAID were translated from English to Turkish by two authors (CM and ÇK), who are both fluent in English and Turkish. Back translations by another translator who was not familiar with the scales indicated no substantive differences with the originals.

Statistical analysis

SPSS version 12 for Windows was used to carry out statistical analyses. In case of missing values on the CESD and the ITAS, a maximum number of 3 items were estimated using the mean of the other completed items of that particular questionnaire. Firstly, demographic, clinical and depression data of two
The purpose of our research was to study whether higher levels of depression symptoms and diabetes-specific distress are associated with a more negative appraisal of insulin therapy, underlying a reluctance to start insulin. Indeed we found that patients with Type 2 diabetes who reported increased levels of depressive symptoms and diabetes-specific distress clearly extend beyond fear of injections alone. Other factors, such as worries about the impact of insulin therapy on the social environment and feelings that insulin therapy signifies that one has failed to manage diabetes with diet/tablets also appear to play a role.

Results

Demographic indices

The total study sample comprised of 154 subjects, of whom 84 were women (55%). A total number of 220 patients were invited, and 154 patients (70%) agreed to participate and met the inclusion criteria. A total 30% of the invited patients did not want to participate or could not participate because being illiterate or not able to read without an optical device. The mean age for women was 56 ± 9 years and for men 57 ± 11 years (total ranging from 28 to 81 years). There were no significant differences between the two clinics regarding gender, age or duration of diabetes. A considerable percentage of the sample appeared to be highly educated (41%). Compared to the male participants, women had a significantly lower level of education. The majority of the individuals were married (84%). The mean HbA1c of the total sample was 6.7 ± 1.0 (4.8–10.0), 63% responded not to have a complication of diabetes. The percentage of missing values was for the CES-D 1.2% and for the ITAS 2.4%. Compared to the patients from the Istanbul University Clinic, high levels of depression scores (CES-D ≥ 16) were significantly more common in the Cerrahpaşa University Hospital: 19% (18/95) versus 32% (18/56, P < 0.05). As to be expected, women had higher mean depression scores compared to male participants (Table 1).

Associations between depression and the appraisal of insulin therapy

The total mean ITAS-score was 54 ± 10. There was no significant difference between male and female participants regarding the appraisal of insulin therapy. The total ITAS score, was significantly higher for depressed patients (mean 56.5, SD 11.1) than for non-depressed patients (mean 52.8, SD 9.5).

Next, in Table 2 it is shown that patients with a high depression score rated insulin therapy more negatively on more than half of the items, compared to patients with lower depression scores. Moreover, 47% of patients with a high depression score had a negative appraisal of insulin therapy on 7 or more ITAS-items, compared to 25 to 29% of those with low-moderate and elevated depression groups (Chi-square, P = 0.086).

Table 3 shows the results of stepwise, multiple regression analyses that were conducted to evaluate whether demographic data, symptoms of depression and diabetes-specific emotional distress were associated with a negative appraisal of insulin therapy (ITAS). Values for VIF and tolerance did not indicate multicollinearity problems. The first regression model included four demographic variables: being female, low level of education, age and duration of diabetes. In this model, patients with a low education tended to have a more negative appraisal of insulin therapy (Beta 0.15, P = 0.08), while the other variables were not significantly associated with appraisal of insulin. In the second model, depression was significantly associated with a more negative appraisal of insulin therapy (Beta: 0.20, P = 0.02). In the third model, diabetes-specific emotional distress was added to the analysis: this resulted in a large drop of the Beta between depression and negative insulin-appraisal from 0.20 to 0.02.

Discussion

The aim of our research was to study whether higher levels of depression symptoms and diabetes-specific distress are associated with a more negative appraisal of insulin therapy, underlying a reluctance to start insulin. Indeed we found that patients with Type 2 diabetes who reported increased levels of depressive symptoms had significantly more negative beliefs about insulin therapy, as measured with the ITAS, compared to non-depressed patients. In the linear regression analyses, depression symptomatology was found to be positively associated with a more negative appraisal of insulin therapy. Adjustment for diabetes-specific emotional problems lowered this to almost zero. Moreover, the positive association between diabetes-distress and a negative insulin appraisal was considerably stronger than the association with depression. This suggests that in insulin-naïve Type 2 diabetes patients, higher levels of diabetes-distress directly contribute to more negative expectations of insulin therapy.

It is important to note that both outpatient samples in our study were in rather good control, with no apparent need to start insulin therapy. Nevertheless, like in the United Kingdom [4] and in the U.S.A. [6,7], a considerable number of the Turkish diabetes patients in our study had negative appraisals of insulin therapy. The patients’ reasons for disliking insulin therapy clearly extend beyond fear of injections alone. Other factors, such as worries about the impact of insulin therapy on the social environment and feelings that insulin therapy signifies that one has failed to manage diabetes with diet/tablets also appear to play a role.
In the present study, we found that 48–68% of the participants agreed to some extend that taking insulin indicates a personal failure, which is in concert with findings from the DAWN study, where 58% of the patients agreed with a comparable statement [7,14]. Requiring insulin therapy is linked to a sense of personal failure, possibly fuelled by common physician practice worldwide, where the prospect of insulin therapy is used as a kind of threat to motivate better patient cooperation [6]. In the present study, we found that 48–68% of the participants agreed to some extend that taking insulin indicates a personal failure, which is in concert with findings from the DAWN study, where 58% of the patients agreed with a comparable statement [7,14]. Requiring insulin therapy is linked to a sense of personal failure, possibly fuelled by common physician practice worldwide, where the prospect of insulin therapy is used as a kind of threat to motivate better patient cooperation [6].

Another interesting finding is more patients (40%) with a high depression score responded that insulin causes weight gain than those reporting less negative affect (12–14%) In the UKPDS, patients taking insulin indeed gained 4 kilograms more than those on diet, over a period of 10 years [4]. Although modern insulin analogues may have a less profound effect on weight than NPH [17], worries about gaining weight are not unrealistic. The fact that depressed patients were the most worried about the weight issue is in line with the depressive realism hypothesis, which posits that depressed people are often more accurate in their perceptions and judgements than non-depressed people are [18].

There are several limitations that need to be mentioned. First, as our data have been collected in two Turkish outpatient clinics in Istanbul, it is important to emphasize that the results might not be representative for other diabetes patients in or outside Turkey. Generally the more complex diabetes patients that the DAWN study [7] did not find a relationship between education and negative attitudes towards insulin may be related to a difference in measurement. Where we used a comprehensive questionnaire, Peyrot and colleagues only asked about perceived efficacy of insulin and self-blame for needing insulin.

In the present study, we found that 48–68% of the participants agreed to some extend that taking insulin indicates a personal failure, which is in concert with findings from the DAWN study, where 58% of the patients agreed with a comparable statement [7,14]. Requiring insulin therapy is linked to a sense of personal failure, possibly fuelled by common physician practice worldwide, where the prospect of insulin therapy is used as a kind of threat to motivate better patient cooperation [6]. In the present study, we found that 48–68% of the participants agreed to some extend that taking insulin indicates a personal failure, which is in concert with findings from the DAWN study, where 58% of the patients agreed with a comparable statement [7,14]. Requiring insulin therapy is linked to a sense of personal failure, possibly fuelled by common physician practice worldwide, where the prospect of insulin therapy is used as a kind of threat to motivate better patient cooperation [6].

Another interesting finding is more patients (40%) with a high depression score responded that insulin causes weight gain than those reporting less negative affect (12–14%) In the UKPDS, patients taking insulin indeed gained 4 kilograms more than those on diet, over a period of 10 years [4]. Although modern insulin analogues may have a less profound effect on weight than NPH [17], worries about gaining weight are not unrealistic. The fact that depressed patients were the most worried about the weight issue is in line with the depressive realism hypothesis, which posits that depressed people are often more accurate in their perceptions and judgements than non-depressed people are [18].

There are several limitations that need to be mentioned. First, as our data have been collected in two Turkish outpatient clinics in Istanbul, it is important to emphasize that the results might not be representative for other diabetes patients in or outside Turkey. Generally the more complex diabetes patients
are referred to university hospitals, and the patients in our study were also relatively highly educated.

Secondly, as the design of our study is cross-sectional, we cannot infer conclusions regarding causality. Yet, it does seem plausible that depression contributes to a more negative attitude towards the use of insulin, rather than the reverse. Furthermore, longitudinal studies are needed to investigate whether lower levels of depression are predictive of a more successful change to insulin therapy. Thirdly, we did not collect data for the patients who refused or were unable to participate.

Table 2 Percentages of subjects who responded to each ITAS item with ‘somewhat agree’ or ‘strongly agree’, for each of the patients with different CESD scores: 0–15 (low/moderate), 16–23 (high depressive symptoms), 24 or more (severe depressive symptoms)

<table>
<thead>
<tr>
<th>Item content</th>
<th>CES-D scores</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0–15</td>
</tr>
<tr>
<td>1-Taking insulin means I have failed to manage my diabetes with diet and tablets.</td>
<td>51%</td>
</tr>
<tr>
<td>2-Taking insulin means my diabetes has become much worse.</td>
<td>41%</td>
</tr>
<tr>
<td>3-Taking insulin helps to prevent complications of diabetes.</td>
<td>52%</td>
</tr>
<tr>
<td>4-Taking insulin means other people see me as a sicker person.</td>
<td>42%</td>
</tr>
<tr>
<td>5-Taking insulin makes life less flexible.</td>
<td>43%</td>
</tr>
<tr>
<td>6-I’m afraid of injecting myself with a needle.</td>
<td>43%</td>
</tr>
<tr>
<td>7-Taking insulin increases the risk of low blood glucose levels (hypoglycaemia).</td>
<td>29%</td>
</tr>
<tr>
<td>8-Taking insulin helps to improve my health.</td>
<td>56%</td>
</tr>
<tr>
<td>9-Insulin causes weight gain.</td>
<td>12%</td>
</tr>
<tr>
<td>10-Managing insulin injections takes a lot of time and energy.</td>
<td>10%</td>
</tr>
<tr>
<td>11-Taking insulin means I have to give up activities I enjoy.</td>
<td>14%</td>
</tr>
<tr>
<td>12-Taking insulin means my health will deteriorate.</td>
<td>22%</td>
</tr>
<tr>
<td>13-Injecting insulin is embarrassing.</td>
<td>4%</td>
</tr>
<tr>
<td>14-Injecting insulin is painful.</td>
<td>11%</td>
</tr>
<tr>
<td>15-It is difficult to inject the right amount of insulin correctly at the right time every day.</td>
<td>27%</td>
</tr>
<tr>
<td>16-Taking insulin makes it more difficult to fulfil my responsibilities (at work, at home).</td>
<td>26%</td>
</tr>
<tr>
<td>17-Taking insulin helps to maintain good control of blood glucose.</td>
<td>58%</td>
</tr>
<tr>
<td>18-Being on insulin causes family and friends to be more concerned about me.</td>
<td>43%</td>
</tr>
<tr>
<td>19-Taking insulin helps to improve my energy level.</td>
<td>40%</td>
</tr>
<tr>
<td>20-Taking insulin makes me more dependent on my doctor.</td>
<td>34%</td>
</tr>
</tbody>
</table>

*P ≤ 0.05; **P ≤ 0.01.

Table 3 Multiple linear regression analyses: associations between a negative appraisal of insulin therapy (total ITAS score), and 1) sociodemographic variables, depression and diabetes-specific emotional distress (PAID survey) in 154 insulin-naive outpatients with type 2 diabetes mellitus

<table>
<thead>
<tr>
<th>Model 1 Sociodemographic</th>
<th>Model 2 Sociodemographic and depression</th>
<th>Model 3 Sociodemographic, depression, diabetes-specific distress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta</td>
<td>t</td>
<td>P</td>
</tr>
<tr>
<td>Female sex</td>
<td>0.07</td>
<td>0.81</td>
</tr>
<tr>
<td>Low education</td>
<td>0.15</td>
<td>1.74</td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.07</td>
<td>0.39</td>
</tr>
<tr>
<td>Duration diabetes (years)</td>
<td>0.07</td>
<td>0.79</td>
</tr>
<tr>
<td>II Depressed mood (enter)</td>
<td>depression symptoms (CES-D)</td>
<td>0.20</td>
</tr>
<tr>
<td>III Diabetes-specific emotional distress</td>
<td>Problem Areas In Diabetes Survey (PAID)</td>
<td>0.39</td>
</tr>
<tr>
<td>Adjusted R²</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>F-change</td>
<td>0.227</td>
<td>0.023</td>
</tr>
</tbody>
</table>
because of reading problems or illiteracy. As a result of this we have no clear indication if or how the non-response could have influenced our results. However, we want to emphasize that the non-response was rather low (30%).

In sum, we can conclude that higher levels of depression and diabetes-specific emotional distress are associated with a significantly more negative appraisal of insulin therapy. Future prospective studies are needed to test whether depression and diabetes-distress are associated with actual postponing insulin therapy and subsequent worsening of glycaemic control.

Competing interests
Nothing to declare.

Acknowledgements
This study was supported by an unrestricted grant from Novo Nordisk Turkey and Novo Nordisk Denmark. The authors wish to express their gratitude to the patients who participated in the present study.

References
3 Pouwer F, Snoek FJ. Association between symptoms of depression and glycemic control may be unstable across gender. Diabetes Med 2001; 18: 593–598.